In Sweden, attenuated androgens and tranexamic acid have been used off‐label for long term prophylaxis in HAE since the 1980s while plasma‐derived C1‐INH was approved for this use as of June 2011. The gene discussed is SERPING1; the disease is hereditary angioedema.